LEA vs. IONS
LEA (Lear Corporation) and IONS (Ionis Pharmaceuticals, Inc.) are both stocks. LEA operates in Auto Parts (Consumer Cyclical), while IONS operates in Biotechnology (Healthcare). Over the past 10 years, LEA returned 4.66%/yr vs 13.21%/yr for IONS. At a 0.26 correlation, their price movements are largely independent.
Performance
LEA vs. IONS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LEA achieves a 20.65% return, which is significantly higher than IONS's -3.94% return. Over the past 10 years, LEA has underperformed IONS with an annualized return of 4.66%, while IONS has yielded a comparatively higher 13.21% annualized return.
LEA
- 1D
- -2.86%
- 1M
- -1.72%
- YTD
- 20.65%
- 6M
- 18.11%
- 1Y
- 54.07%
- 3Y*
- 2.77%
- 5Y*
- -2.87%
- 10Y*
- 4.66%
IONS
- 1D
- 0.13%
- 1M
- 0.57%
- YTD
- -3.94%
- 6M
- -5.40%
- 1Y
- 101.73%
- 3Y*
- 24.22%
- 5Y*
- 14.60%
- 10Y*
- 13.21%
LEA vs. IONS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LEA Lear Corporation | 20.65% | 24.86% | -31.17% | 16.40% | -30.70% | 16.20% | 16.90% | 14.38% | -29.29% | 35.23% |
IONS Ionis Pharmaceuticals, Inc. | -3.94% | 126.29% | -30.90% | 33.94% | 24.12% | -46.18% | -6.41% | 11.75% | 7.48% | 5.16% |
Correlation
The correlation between LEA and IONS is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.25 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since Nov 9, 2009 | 0.26 |
Fundamentals
LEA:
$7.05B
IONS:
$12.53B
LEA:
$9.98
IONS:
-$1.95
LEA:
0.31
IONS:
12.03
LEA:
2.18
IONS:
25.50
LEA:
$23.52B
IONS:
$1.06B
LEA:
$1.26B
IONS:
$1.04B
LEA:
$1.20B
IONS:
$4.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LEA vs. IONS — Risk / Return Rank
LEA
IONS
LEA vs. IONS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Lear Corporation (LEA) and Ionis Pharmaceuticals, Inc. (IONS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LEA | IONS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.54 | ||
| Sortino ratioReturn per unit of downside risk | -1.62 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.49 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | 2.86 | 5.26 | -2.40 |
| Martin ratioReturn relative to average drawdown | 6.91 | 12.39 | -5.48 |
Loading charts...
Drawdowns
LEA vs. IONS - Drawdown Comparison
The maximum LEA drawdown since its inception was -64.51%, smaller than the maximum IONS drawdown of -91.42%. Use the drawdown chart below to compare losses from any high point for LEA and IONS.
Loading charts...
Drawdown Indicators
| LEA | IONS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -64.51% | -91.42% | +26.91% |
Max Drawdown (1Y)Largest decline over 1 year | -18.98% | -19.45% | +0.47% |
Max Drawdown (3Y)Largest decline over 3 years | -49.42% | -52.36% | +2.94% |
Max Drawdown (5Y)Largest decline over 5 years | -57.83% | -52.36% | -5.47% |
Max Drawdown (10Y)Largest decline over 10 years | -64.51% | -70.39% | +5.88% |
Current DrawdownCurrent decline from peak | -24.02% | -12.15% | -11.87% |
Average DrawdownAverage peak-to-trough decline | -19.83% | -52.35% | +32.52% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.85% | 8.24% | -0.39% |
Volatility
LEA vs. IONS - Volatility Comparison
Lear Corporation (LEA) has a higher volatility of 8.63% compared to Ionis Pharmaceuticals, Inc. (IONS) at 6.42%. This indicates that LEA's price experiences larger fluctuations and is considered to be riskier than IONS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LEA | IONS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.63% | 6.42% | +2.21% |
Volatility (6M)Calculated over the trailing 6-month period | 24.64% | 20.05% | +4.59% |
Volatility (1Y)Calculated over the trailing 1-year period | 32.76% | 46.63% | -13.87% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 34.05% | 42.20% | -8.15% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 35.35% | 46.17% | -10.82% |
Dividends
LEA vs. IONS - Dividend Comparison
LEA's dividend yield for the trailing twelve months is around 2.25%, while IONS has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IONS Ionis Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LEA Lear Corporation | 2.25% | 2.69% | 3.25% | 2.18% | 2.48% | 0.97% | 0.64% | 2.19% | 2.28% | 1.13% | 0.91% | 0.81% |
Financials
LEA vs. IONS - Financials Comparison
This section allows you to compare key financial metrics between Lear Corporation and Ionis Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LEA vs. IONS - Profitability Comparison
LEA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Lear Corporation reported a gross profit of 0.00 and revenue of 5.82B. Therefore, the gross margin over that period was 0.0%.
IONS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ionis Pharmaceuticals, Inc. reported a gross profit of 243.11M and revenue of 246.09M. Therefore, the gross margin over that period was 98.8%.
LEA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Lear Corporation reported an operating income of 0.00 and revenue of 5.82B, resulting in an operating margin of 0.0%.
IONS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ionis Pharmaceuticals, Inc. reported an operating income of -117.42M and revenue of 246.09M, resulting in an operating margin of -47.7%.
LEA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Lear Corporation reported a net income of 172.30M and revenue of 5.82B, resulting in a net margin of 3.0%.
IONS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ionis Pharmaceuticals, Inc. reported a net income of -92.53M and revenue of 246.09M, resulting in a net margin of -37.6%.
Frequently Asked Questions
LEA and IONS have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LEA has higher volatility (8.63%) compared to IONS (6.42%). In terms of maximum drawdown, LEA dropped -64.51% vs IONS's -91.42%.
IONS currently has the higher Sharpe Ratio (2.19 vs 1.66), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LEA and IONS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer